Copyright
©The Author(s) 2021.
World J Clin Cases. Dec 16, 2021; 9(35): 10979-10993
Published online Dec 16, 2021. doi: 10.12998/wjcc.v9.i35.10979
Published online Dec 16, 2021. doi: 10.12998/wjcc.v9.i35.10979
Ref. | Intervention | Stent manufacturer and typea | Outcomes |
Chen et al[25], 2012 | 125I seed strands performed after stent insertion | Nitinol self-expendable stent (Luminexx III; BARD); Type I | Laboratory values before and after stent placement, complications, stent patency |
Conventional stent | |||
Hasimu et al[13], 2017 | Biliary stent with 125I seed strands | Nitinol self-expandable stent (S.M.A.R.T.; Cordis Corporation, Miami Lakes, FL, United States); Type III | Stent patency, survival, relief of symptoms, technical and clinical success, complications, laboratory values before and after stent placement, radiation safety |
Conventional stent | |||
Chen et al[26], 2018 | 125I seeds-loaded-biliary stent | Self-expendable stent (produced by Mirco-tech, Nanjing, China); Type II | Laboratory values before and after stent placement, complications, stent patency, survival, CR, PR, SD, PD |
Conventional stent | |||
Jiao et al[14], 2017 | SEMS with 125I seed strands | A Nitinol self-expendable stent (Niti-S Biliary stent, Taewoong, Seoul, Korea); Type I | Technical success, laboratory values before and after stent placement, stent patency, overall survival, early or late complications |
Conventional stent | |||
Zhu et al[20], 2012 | 125I seeds-loaded-biliary stent | Outer self-expandable 125I radioactive seeds-loaded stent and inner conventional self-expanding biliary nitinol alloy stent (Nanjing MicroInvasive Medical Inc., Nanjing, China); Type II | Technical success, jaundice relief, radiation safety, complications (subjective and objective), survival, stent patency, laboratory values before and after stent placement |
Conventional stent | |||
Zhu et al[21], 2018 | 125I seeds-loaded-biliary stent | Inner conventional uncovered SEMS (Nanjing Micro-Tech Co. Ltd., Nanjing, China) and outer 125I seed-Xloaded stent; Type II | Stent restenosis, patency time, technical success, relief of jaundice, survival, complications |
Conventional stent | |||
Pan et al[15], 2020 | Biliary stent with 125I seed strands | Biliary stent (E-Luminexx Biliary Stent; Wachhausstrasse 6D76227, BARD Corporation, Karlsruhe, Germany); Type III | Stent patency, overall survival, complications, laboratory values before and after stent placement, independent factors associated with survival |
Conventional stent | |||
Wang et al[24], 2017 | Biliary stent with 125I seed strands | Biliary internal stent (Micro-Tech Co., Ltd. Nanjing, China); Type I | Success rate, laboratory values before and after stent placement, stent patency, survival |
Conventional stent | |||
Zhou et al[22], 2019 | UCSEMS with 125I seed strands | Three types of SEMS [E-Luminexx (Bard Peripheral Vascular, Tempe, AZ, United States), S.M.A.R.T (Cordis, Milpitas, CA, United States), and Zilver (Cook Medical, Bloomington, IN, United States)];Type III | Technical success, clinical success, complications, follow-up time, stent patency, survival, laboratory values before and after stent placement |
UCSEMS | |||
Zhou et al[23], 2020 | SEMS with 125I seed strands | Self-expandable metallic stent (Cook Medical, Bloomington, IN, United States); Type III | Technical success, clinical success, laboratory values before and after stent placement, complications, overall survival, and stent patency |
Conventional stent |
- Citation: Chen WY, Kong CL, Meng MM, Chen WQ, Zheng LY, Mao JT, Fang SJ, Chen L, Shu GF, Yang Y, Weng QY, Chen MJ, Xu M, Ji JS. Percutaneous biliary stent combined with brachytherapy using 125I seeds for treatment of unresectable malignant obstructive jaundice: A meta-analysis. World J Clin Cases 2021; 9(35): 10979-10993
- URL: https://www.wjgnet.com/2307-8960/full/v9/i35/10979.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i35.10979